Article, News
Prescient Therapeutics reports positive safety data from PTX-100 study on T-cell lymphoma patients
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and refractory T-cell lymphomas (TCL) continues to show encouraging clinical activity…
News
Prescient Therapeutics – Meeting on The Mesa 2022
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the Cell & Gene Meeting on the Mesa in October 2022…
Article, News
Prescient Therapeutics A$2.5 million top-up placement brings raise total to A$11.3 million
Prescient Therapeutics Ltd (ASX:PTX) has brought in another A$2.5 million in a top-up placement to cater for strong investor demand. Late last week, the clinical-stage oncology…
Article, News
Prescient Therapeutics exceeds SPP target, delivers top-up placement to accommodate demand
“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing director and CEO Steven Yatomi-Clarke.
Article, News
Prescient Therapeutics at forefront of overcoming challenges, with game-changing CAR-T cell cancer therapies
CAR-T therapy is leading the race as the holy grail to cure cancer but like many medical therapies it is not without problems, which Prescient Therapeutics…
Article, News
The cancer-fighting tech disabling ‘force fields’ around tumours
SX-listed biotech Prescient Therapeutics has unveiled the second component of its CellPryme cell therapy enhancement platform on stage at the prestigious CAR-TCR Summit in Boston….
Article, News
Prescient Therapeutics debuts CellPryme-A at world’s largest CAR-TCR meeting in Boston
At the world’s largest CAR-TCR meeting, Prescient Therapeutics (ASX: PTX) has debuted CellPryme-A, which is a novel adjuvant designed to be administered to cancer patients in combination…
Article, News
Prescient unveils latest big hitter CellPryme-A at prestigious Boston CAR-TCR meeting
Prescient has unveiled the latest technology in its cancer-fighting portfolio CellPryme-A at the 7th annual CAR-TCR Summit in Boston, the world’s pre-eminent forum in the CAR…
Article, News
Biotechnology investing for the social good – making money and a difference
There are many foundations and charities which aim to tackle health conditions through funding medical research to develop better treatment options, improve patient outcomes and…